Fig. 2
From: HIV therapeutic vaccine enhances non-exhausted CD4+ T cells in a randomised phase 2 trial
Study design. The six immunisations with VAC-3S between week 0 and week 44 are indicated by arrows, and the first and second end points by closed bars
